Athira Pharma Inc
ATHA0.381USD
+0.011+2.92%
交易中 （美东）报价延迟15分钟
14.88M总市值
亏损市盈率 TTM
关于 Athira Pharma Inc 公司
Athira Pharma, Inc. 是一家处于临床后期的生物制药公司。该公司专注于开发用于恢复神经元健康和减缓神经退化的小分子。该公司的产品线包括用于中枢神经系统 (CNS)、周围神经系统和其他适应症的血脑屏障可渗透和外周受限的候选药物。其主要候选药物 fosgonimeton (ATH-1017) 是一种皮下给药的小分子正向调节剂，可调节肝细胞生长因子/间充质上皮转化因子 (HGF/MET) 系统，用于治疗中枢神经系统疾病。该公司还在评估其他候选药物，以用于治疗神经性疼痛、肌萎缩侧索硬化症、帕金森病和其他神经退行性疾病。该公司的 ATH-1020 已在健康志愿者中完成了 I 期单次递增剂量评估。该公司的 ATH-1105 是一种小分子化合物，旨在作为口服、每日一次的治疗方法，以增强 HGF/MET 系统。
公司简介
公司代码ATHA
公司名称Athira Pharma Inc
上市日期Sep 18, 2020
CEODr. Mark James Litton, Ph.D.
员工数量26
证券类型Ordinary Share
年结日Sep 18
公司地址18706 North Creek Parkway, Suite 104
城市BOTHELL
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编98011
电话14256208501
网址https://www.athira.com/
公司代码ATHA
上市日期Sep 18, 2020
CEODr. Mark James Litton, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
345.49K
-6.78%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
168.90K
-4.81%
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
111.88K
-7.08%
Mr. Robert Renninger
Mr. Robert Renninger
Senior Vice President - Finance, Accounting
Senior Vice President - Finance, Accounting
109.19K
-2.58%
Ms. Kelly A. Romano
Ms. Kelly A. Romano
Independent Chairwoman of the Board
Independent Chairwoman of the Board
80.72K
-23.06%
Dr. Javier San Martin, M.D.
Dr. Javier San Martin, M.D.
Chief Medical Officer
Chief Medical Officer
71.67K
-13.14%
Mr. Grant E. Pickering
Mr. Grant E. Pickering
Independent Director
Independent Director
25.78K
--
James A. Johnson ,
James A. Johnson ,
Independent Director
Independent Director
5.00K
--
Ms. Barbara Kosacz, J.D.
Ms. Barbara Kosacz, J.D.
Independent Director
Independent Director
--
--
Ms. Julie Rathbun
Ms. Julie Rathbun
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
345.49K
-6.78%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
168.90K
-4.81%
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
111.88K
-7.08%
Mr. Robert Renninger
Mr. Robert Renninger
Senior Vice President - Finance, Accounting
Senior Vice President - Finance, Accounting
109.19K
-2.58%
Ms. Kelly A. Romano
Ms. Kelly A. Romano
Independent Chairwoman of the Board
Independent Chairwoman of the Board
80.72K
-23.06%
Dr. Javier San Martin, M.D.
Dr. Javier San Martin, M.D.
Chief Medical Officer
Chief Medical Officer
71.67K
-13.14%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月4日 周五
更新时间: 7月4日 周五
持股股东
股东类型
持股股东
持股股东
占比
Perceptive Advisors LLC
13.84%
BML Capital Management LLC
8.20%
Nemean Asset Management, LLC
5.11%
The Vanguard Group, Inc.
3.94%
Propel Bio Management, LLC
3.82%
Other
65.09%
持股股东
持股股东
占比
Perceptive Advisors LLC
13.84%
BML Capital Management LLC
8.20%
Nemean Asset Management, LLC
5.11%
The Vanguard Group, Inc.
3.94%
Propel Bio Management, LLC
3.82%
Other
65.09%
股东类型
持股股东
占比
Investment Advisor
18.80%
Private Equity
14.16%
Corporation
5.12%
Venture Capital
3.94%
Hedge Fund
3.71%
Individual Investor
3.67%
Investment Advisor/Hedge Fund
2.40%
Research Firm
1.16%
Family Office
1.09%
Other
45.95%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
148
20.73M
53.10%
-5.78M
2025Q1
186
20.71M
53.09%
-9.10M
2024Q4
198
21.17M
54.25%
-10.35M
2024Q3
213
18.84M
48.90%
-11.53M
2024Q2
229
24.92M
64.90%
-5.72M
2024Q1
248
24.36M
63.46%
-12.25M
2023Q4
255
24.39M
64.09%
-12.11M
2023Q3
262
25.40M
66.77%
-11.45M
2023Q2
269
26.01M
68.55%
-12.86M
2023Q1
277
27.79M
73.28%
-11.27M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Perceptive Advisors LLC
5.40M
13.84%
--
--
Apr 04, 2025
BML Capital Management LLC
3.20M
8.2%
+424.78K
+15.30%
Mar 31, 2025
Nemean Asset Management, LLC
1.99M
5.11%
+1.99M
--
Apr 14, 2025
The Vanguard Group, Inc.
1.54M
3.94%
-18.74K
-1.20%
Mar 31, 2025
Propel Bio Management, LLC
1.49M
3.82%
--
--
Mar 31, 2025
Simplify Asset Management Inc
1.49M
3.82%
--
--
Mar 31, 2025
Tang Capital Management, LLC
600.00K
1.54%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
446.47K
1.14%
-1.54K
-0.34%
Mar 31, 2025
Acadian Asset Management LLC
428.53K
1.1%
-5.96K
-1.37%
Mar 31, 2025
BofA Global Research (US)
416.16K
1.07%
+15.00
+0.00%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Simplify Propel Opportunities ETF
0.67%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
0%
iShares Neuroscience and Healthcare ETF
0%
iShares US Small-Cap Equity Factor ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Simplify Propel Opportunities ETF
占比0.67%
Dimensional US Core Equity 1 ETF
占比0%
iShares Micro-Cap ETF
占比0%
iShares Neuroscience and Healthcare ETF
占比0%
iShares US Small-Cap Equity Factor ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
